Literature DB >> 15701269

Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion.

Troy F Kimsey1, A S Campbell, D Albo, M Wilson, Thomas N Wang.   

Abstract

PURPOSE: Macrophage inflammatory protein-3alpha (Mip-3alpha) is par t of a family of chemotactic cytokines involved in recruiting inflammatory cells throughout the body. CCR6 is a G-protein-linked, seven-transmembrane receptor that is highly specific for Mip-3alpha. The role of Mip-3alpha has been well defined in several inflammatory conditions, but its role has not been well defined in neoplastic processes. Mip-3alpha has been shown to promote pancreatic cancer cell migration, but no studies have demonstrated the effect of Mip-3alpha on pancreatic cancer cell invasion. We hypothesize that Mip-3alpha and its CCR6 receptor promote pancreatic cancer cell invasion.
MATERIALS AND METHODS: Immunohistochemical staining was per formed for Mip-3alpha and CCR6 in pancreatic cancer tissue and the human pancreatic cancer cell line PANC-1. RNA was isolated from PANC-1 cancer cells, and the presence of Mip-3alpha messenger RNA in PANC-1 cancer cells was determined by reverse transcriptase polymerase chain reaction. PANC-1 cancer cell invasion of type IV collagen was evaluated in the presence of Mip-3alpha and anti-CCR6 antibody with the use of a modified Boyden chamber invasion assay.
RESULTS: Co-localization of Mip-3alpha and its CCR6 receptor in pancreatic cancer was confirmed using immunohistochemical staining for Mip-3alpha and its CCR6 receptor and reverse transcriptase polymerase chain reaction for Mip-3alpha. Immunohistochemical staining of pancreatic cancer tissue and the PANC-1 cancer cell line showed positive staining for Mip-3alpha and its CCR6 receptor within the cancer cells. Staining was also positive for Mip-3alpha within stromal cells adjacent to the cancer cells in pancreatic cancer tissue. Reverse transcriptase polymerase chain reaction demonstrated the presence of Mip-3alpha messenger RNA within PANC-1 cancer cells. Invasion studies showed that increasing concentrations of Mip-3alpha promoted a dose-dependent increase in pancreatic cancer cell invasion of type IV collagen. The addition of 100 ng/mL of Mip-3alpha promoted a threefold increase in pancreatic cancer cell invasion over that of the control group. Anti-CCR6 antibody inhibited Mip-3alpha-stimulated PANC-1 cancer cell invasion of type IV collagen by 63%. DISCUSSION: Co-localization of Mip-3alpha and its CCR6 receptor promotes pancreatic cancer cell invasion of type IV collagen. This finding continues to highlight the importance that inflammation plays in the progression of pancreatic cancer. As the relationship between the inflammatory and neoplastic processes involved with pancreatic cancer becomes better defined, therapies targeting the inflammatory process may help prevent pancreatic cancer invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15701269     DOI: 10.1097/00130404-200411000-00007

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  35 in total

1.  Expression of the chemokine receptor CCR6 correlates with a favorable prognosis in patients with adenocarcinoma of the lung.

Authors:  Yoshihiro Minamiya; Hajime Saito; Naoko Takahashi; Manabu Ito; Hiroshi Toda; Takashi Ono; Hayato Konno; Satoru Motoyama; Jun-Ichi Ogawa
Journal:  Tumour Biol       Date:  2010-09-25

2.  Epidermal Smad4 deletion results in aberrant wound healing.

Authors:  Philip Owens; Erin Engelking; Gangwen Han; Sarah M Haeger; Xiao-Jing Wang
Journal:  Am J Pathol       Date:  2009-12-03       Impact factor: 4.307

3.  Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.

Authors:  Sophie Kirshberg; Uzi Izhar; Gail Amir; Jonathan Demma; Fiona Vernea; Katia Beider; Zippora Shlomai; Hanna Wald; Gideon Zamir; Oz M Shapira; Amnon Peled; Ori Wald
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

4.  CCR6 overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer.

Authors:  X G Zhang; B T Song; F J Liu; D Sun; K X Wang; H Qu
Journal:  Clin Transl Oncol       Date:  2015-10-21       Impact factor: 3.405

5.  Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma.

Authors:  Xiao-Peng Zhang; Zhi-Juan Hu; Ai-Hong Meng; Guo-Chen Duan; Qing-Tao Zhao; Jing Yang
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

Review 6.  Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve.

Authors:  Noelle Jurcak; Lei Zheng
Journal:  Pharmacol Ther       Date:  2019-04-29       Impact factor: 12.310

Review 7.  Clinical utilization of chemokines to combat cancer: the double-edged sword.

Authors:  Chiara Dell'Agnola; Arya Biragyn
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

8.  Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases.

Authors:  Claudia Rubie; Vilma Oliveira Frick; Mathias Wagner; Christina Weber; Bianca Kruse; Katja Kempf; Jochen König; Bettina Rau; Martin Schilling
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

9.  CCL20/CCR6 expression profile in pancreatic cancer.

Authors:  Claudia Rubie; Vilma Oliveira Frick; Pirus Ghadjar; Mathias Wagner; Henner Grimm; Benjamin Vicinus; Christoph Justinger; Stefan Graeber; Martin K Schilling
Journal:  J Transl Med       Date:  2010-05-10       Impact factor: 5.531

10.  Mutations in BALB mitochondrial DNA induce CCL20 up-regulation promoting tumorigenic phenotypes.

Authors:  James Sligh; Jaroslav Janda; Jana Jandova
Journal:  Mutat Res       Date:  2014-11       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.